医学影像技术研究商NVision Imaging获得5500万美元B轮融资，将从量子传感转向计算领域-动脉网

NVision expands its quantum platform for drug development and secures $55 million

D-Pharm 等信源发布 2026-05-26 09:33



可切换为仅中文







NVision announced a $55 million

NVision 宣布了 5500 万美元的资金筹集

Series B financing

B轮融资

round anchored by Abbott. The company also announced a major expansion from quantum sensing into

由Abbott主导的这一轮。公司还宣布了从量子传感到的重大扩展

quantum computing

量子计算

, advancing its efforts to build an end to end, quantum based approach to designing and validating

，推动其构建端到端、基于量子的设计和验证方法的努力向前发展

therapies

疗法

。

The company’s quantum-enhanced sensing platform, POLARIS, already uses quantum technology to boost the MRI signal of sugar-based imaging agents by orders of magnitude, enabling real-time measurement of metabolism on standard MRI systems. This allows researchers to assess treatment response within hours to days based on disease biology, rather than relying on traditional imaging that can take up to months to show changes in morphology..

该公司的量子增强传感平台 POLARIS 已经利用量子技术将基于糖的成像剂的 MRI 信号增强了几个数量级，从而能够在标准 MRI 系统上实时测量代谢。这使得研究人员可以根据疾病生物学特性，在数小时到数天内评估治疗反应，而不必依赖可能需要数月才能显示形态变化的传统成像方法。

Building on the quantum molecular approach behind POLARIS, NVision is now extending its platform into quantum computation. While developing its MRI signal enhancement technology, NVision discovered a new class of organic molecule-based qubits. With this expansion, NVision lays the foundation for a new quantum-driven approach to drug development.

基于POLARIS背后的量子分子方法，NVision现在正在将其平台扩展到量子计算领域。在开发其MRI信号增强技术的过程中，NVision发现了一类新的基于有机分子的量子比特。通过这一扩展，NVision为药物开发的全新量子驱动方法奠定了基础。

Quantum computing will enable the design of more effective drug candidates, including for previously inaccessible targets, while quantum-enhanced MRI with POLARIS will rapidly validate them in the real biological environment. Together, this will establish a unified “compute and validate” approach, combining quantum computing for design with quantum sensing for real-world validation..

量子计算将能够设计出更有效的候选药物，包括针对以前无法触及的目标，而配备POLARIS的量子增强型核磁共振成像将迅速在真实的生物环境中验证它们。这种结合将建立一个统一的“计算与验证”方法，将用于设计的量子计算与用于现实世界验证的量子传感相结合。

Isomorphic Labs raises $2.1 Billion to scale its AI drug design engine

Isomorphic Labs筹集21亿美元以扩展其AI药物设计引擎

Read news

读新闻

POLARIS systems are already being installed at leading cancer centers worldwide and are expected to be deployed in approximately 20 centers across the U.S., Europe, and Asia by the end of the year. Sites include Memorial Sloan Kettering Cancer Center, the University of Cambridge, and the Technical University of Munich.

POLARIS系统已经在世界领先的癌症中心安装，并预计将在今年年底前部署在美国、欧洲和亚洲的大约20个中心。这些地点包括纪念斯隆凯特琳癌症中心、剑桥大学以及慕尼黑工业大学。

Importantly, POLARIS operates as a practical quantum device in real hospital environments and does not require specialized quantum expertise, demonstrating that quantum technologies can already deliver value today..

重要的是，POLARIS 作为一种实用的量子设备在真实的医院环境中运行，且不需要专门的量子技术专业知识，这表明量子技术如今已能够带来价值。

Drawing on the experience with POLARIS, NVision is extending the same molecular approach into quantum computing. The architecture is designed from first principles with scalability as a requirement. At its core are single photon emitting organic molecules forming an entirely new class of qubits, fundamentally different from legacy approaches. .

借鉴POLARIS的经验，NVision正在将相同的分子方法扩展到量子计算领域。该架构从第一性原理出发设计，并以可扩展性为要求。其核心是由单光子发射有机分子组成的一类全新量子比特，与传统方法有根本性不同。

The new qubits are now being integrated as a thin organic layer directly onto photonic chips, forming the basis of NVision’s quantum computing platform: Photonic Integrated Quantum Circuits (PIQC, pronounced “Pixie”). By combining this molecular layer with established photonic hardware, the approach enables a scalable path to building quantum computers using standard semiconductor manufacturing technologies..

新的量子比特现在正作为一层薄薄的有机层直接集成到光子芯片上，构成了NVision量子计算平台的基础：光子集成量子电路（PIQC，发音为“Pixie”）。通过将这一分子层与现有的光子硬件相结合，该方法为使用标准半导体制造技术构建量子计算机提供了一条可扩展的路径。

“I see a future where quantum computers generate an explosion of drug hypotheses for diseases that are exceptionally difficult to treat today,” said Sella Brosh, CEO and Co-Founder of NVision. “As we expand our ambition into quantum computing, building on our remarkable new class of organic molecule-based qubits, that future comes closer.

“我看到未来量子计算机为当今极难治疗的疾病生成大量药物假设，”NVision首席执行官兼联合创始人塞拉·布罗什表示。“随着我们将雄心扩展到量子计算领域，并基于我们卓越的新型有机分子量子比特，那个未来正变得越来越近。”

But without translational speed, we won’t fully realize those gains. POLARIS is built exactly to address this, enabling rapid in-vivo validation and closing the loop between design and reality.”.

但是，如果没有转化速度，我们就无法完全实现这些成果。POLARIS 的设计正是为了解决这一问题，能够实现快速的体内验证，并弥合设计与现实之间的差距。

“NVision is fundamentally changing how we find, diagnose, and treat cancer by making the biology of disease visible in ways that weren’t possible before,” said Peter Barrett, General Partner, Playground Global. “That same molecular quantum capability now enables both the design and testing of new therapies - defining a new category in quantum health.”.

“NVision 从根本上改变了我们发现、诊断和治疗癌症的方式，它以前所未有的方式使疾病的生物学特性变得可见，” Playground Global 的普通合伙人彼得·巴雷特 (Peter Barrett) 表示。“同样的分子量子能力现在可以实现新疗法的设计和测试——定义了量子健康新的类别。”

To support this expansion, NVision also announced $55 million in new funding. The Series B includes a $17 million venture loan from the European Investment Bank (EIB). The round is anchored by Abbott, a global leader in diagnostics and medical devices, with participation from Playground Global, Matterwave/b2ventures, Entrée Capital, and others.

为了支持这一扩展，NVision还宣布了5500万美元的新融资。B轮融资包括欧洲投资银行（EIB）提供的1700万美元风险贷款。本轮融资由全球诊断和医疗设备领域的领导者雅培领投，参与者包括Playground Global、Matterwave/b2ventures、Entrée Capital等。

The new funding brings NVision’s total capital raised to $120 million..

这笔新资金使 NVision 筹集的总资本达到 1.2 亿美元。

Abbott joins as the sole strategic investor in diagnostics, reflecting its interest in exploring how NVision’s quantum technologies can be applied across the diagnostic field. The investment provides Abbott with early access to emerging capabilities in quantum sensing and computing, supporting the evaluation of future applications in disease detection, monitoring, and clinical decision-making..

Abbott作为唯一的战略投资者加入诊断领域，这反映了其对探索NVision的量子技术如何在诊断领域应用的兴趣。这项投资使Abbott能够早期获取量子传感和计算领域的新兴能力，有助于评估未来在疾病检测、监测和临床决策中的应用。

‍Peter Karabatsos, Divisional Vice President of New Technology at Abbott:‍ “At Abbott, we are constantly exploring technologies that can redefine how we understand and diagnose disease. What stands out to us about NVision is their ability to turn complex quantum science into scalable systems for real-world use.

Abbott新任技术部门副总裁Peter Karabatsos表示：“在Abbott，我们一直在探索能够重新定义我们对疾病的理解和诊断的技术。NVision让我们印象深刻的是他们能够将复杂的量子科学转化为适用于现实世界的可扩展系统。

We are particularly interested in how quantum technologies can provide earlier insight into disease biology and new ways to understand complex biological systems and data. The field is still early, and we see this as an opportunity to learn, engage closely, and explore how these capabilities may shape the future of healthcare.”.

我们对量子技术如何能够更早地洞察疾病生物学，以及如何以新的方式理解复杂的生物系统和数据特别感兴趣。该领域尚处于早期阶段，我们认为这是一个学习、深入参与并探索这些能力如何塑造医疗保健未来的机会。"

‍Nicola Beer, Vice President of the European Investment Bank:‍ “At the EIB, we support innovation that has the potential to improve people’s lives. NVision shows how cutting‑edge research can translate into concrete benefits for patients and healthcare systems alike, while strengthening Europe’s innovation ecosystem.

欧洲投资银行副总裁尼古拉·贝尔： “在欧洲投资银行，我们支持有可能改善人民生活的创新。NVision展示了前沿研究如何转化为患者和医疗系统的具体利益，同时加强欧洲的创新生态系统。

We are pleased to accompany the company in this important phase of growth.”.

我们很高兴在公司这一重要的增长阶段为其提供支持。

‍Christian Reitberger, Partner at Matterwave Ventures:‍ “Since our initial investment in 2017, NVision has developed into a molecular spin-control powerhouse. NVision is among a tiny elite of companies already selling commercially useful quantum sensing systems at scale today. Expanding downstream metabolic imaging with upstream simulation capabilities will create a unique combination for quantum boosted large scale pharma R&D utility.”.

克里斯蒂安·雷特贝格，Matterwave Ventures合伙人：“自2017年我们初次投资以来，NVision已发展成为分子自旋控制领域的领军者。NVision是当今少数几家已经大规模销售商业用途量子传感系统的精英公司之一。通过上游模拟能力扩展下游代谢成像，将为量子增强的大规模制药研发应用创造独特组合。”

‍Ran Achituv, Manager Partner at Entrée Capital:‍ “NVision proves that quantum isn’t just about the future. It’s already transforming how we measure and understand biology. Their scalable, clinical-grade sensing platform has the potential to redefine MRI and unlock entirely new biological signals. Now, by bringing quantum computing into healthcare as well, they are building a true one-stop platform for quantum-driven healthcare.

Entrée Capital的管理合伙人Ran Achituv表示：“NVision证明了量子技术不仅仅是关乎未来，它已经在改变我们测量和理解生物学的方式。他们可扩展的临床级传感平台有潜力重新定义核磁共振成像，并解锁全新的生物信号。如今，通过将量子计算引入医疗领域，他们正在打造一个真正的量子驱动医疗一站式平台。”

This is the kind of company that reshapes industries, and we’re proud to have been with them from day one and as they scale.”.

这是一家重塑行业的公司，我们为从一开始就与他们合作并在他们扩展规模时继续合作感到自豪。”

https://www.bionity.com/en/news/1188759/nvision-expands-its-quantum-platform-for-drug-development-and-secures-55-million.html

PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes

PhoreMost 将 B 轮融资扩展至 5000 万美元，以推进高价值的肿瘤学和炎症降解剂项目。

Read news

阅读新闻